Emblaveo™ (aztreonam/avibactam) – New drug approval
February 7, 2025 - AbbVie announced the FDA approval of Emblaveo (aztreonam/avibactam), in combination with metronidazole, in patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI) including those caused by the following susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
Top